Neurology

IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.

Neurology

Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D

Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

Neurology

Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G, Edan G, Clanet M

Analysis of antibody gene rearrangement, usage, and specificity in chronic focal encephalitis.

Neurology

Baranzini SE, Laxer K, Saketkhoo R, Elkins MK, Parent JM, Mantegazza R, Oksenberg JR

Paroxysmal dystonia (tonic spasm) in multiple sclerosis.

Neurology

Waubant E, Alizé P, Tourbah A, Agid Y

Future directions for epilepsy research.

Neurology

Jacobs MP, Fischbach GD, Davis MR, Dichter MA, Dingledine R, Lowenstein DH, Morrell MJ, Noebels JL, Rogawski MA, Spencer SS, Theodore WH

Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group.

Neurology

Hauser SL, Oksenberg JR, Lincoln R, Garovoy J, Beck RW, Cole SR, Moke PS, Kip KE, Gal RL, Long DT

Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.

Neurology

Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis.

Neurology

Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, Mocci S

Pages